AbbVie's next-generation immunology drugs Skyrizi and Rinvoq are now selling faster than Humira is falling, with Skyrizi alone topping $5.5 billion in a single quarter. After years defined by Humira's Patent cliff, the question is whether AbbVie has finally turned the page.

For much of the past three years, AbbVie's story has been dominated by one word: Humira. The world's best-selling drug lost US exclusivity in 2023, and the resulting Revenue decline — the so-called 'Humira hangover' — has shadowed the stock ever since. AbbVie's second-quarter 2026 results, reported on 31 July, suggested that chapter may be closing. Skyrizi delivered $5.5 billion of quarterly sales, and the company raised its full-year outlook.

Yet the market's reaction was cautious: the shares slipped despite a revenue beat, as adjusted Earnings came in below consensus. AbbVie is a Chicago-based pharmaceutical major and a long-standing Dividend payer, and the headline asks whether its immunology successors can decisively outrun Humira's decline. On the evidence of the latest quarter, the case is increasingly compelling — but not without complications.

What the Company Does

AbbVie is a research-based biopharmaceutical company spun out of Abbott Laboratories in 2013. Its portfolio spans immunology, oncology, neuroscience, aesthetics and eye care. The immunology Franchise is the centre of gravity: Humira (adalimumab), historically the group's blockbuster, and its two designated successors, Skyrizi (risankizumab) for psoriasis, psoriatic arthritis and inflammatory bowel disease, and Rinvoq (upadacitinib), an oral JAK inhibitor used across rheumatology, dermatology and gastroenterology.

Beyond immunology, AbbVie sells cancer therapies including Imbruvica and Venclexta, neuroscience products such as Vraylar, and the Botox therapeutic and aesthetic franchises acquired through Allergan, alongside a migraine portfolio. This Diversification means AbbVie is far more than an immunology pure-play, but immunology remains the single biggest determinant of whether group growth resumes after the Humira cliff.

Why the Stock Is in Focus

The catalyst is the crossover moment: Skyrizi and Rinvoq are now scaling fast enough to more than offset Humira's erosion. In the quarter, total immunology revenue reached $8.8 billion, up 14.6% operationally, even as Humira fell 36.1% to $756 million. Skyrizi rose about 24% operationally and Rinvoq about 23.7%. AbbVie also raised full-year revenue guidance and, in June, agreed to acquire Apogee Therapeutics for roughly $10.9 billion, deepening its immunology pipeline.

Investors care because AbbVie has effectively been running a race against its own patent cliff. If the successor drugs can sustain double-digit growth, the group returns to reliable top-line expansion; if they plateau, the Humira drag lingers. The Q2 print offered the clearest sign yet that the successors are winning — though a below-consensus earnings figure tempered enthusiasm, and the shares eased on the day.

Latest Financial Picture

AbbVie reported total net revenues of $16.99 billion, up 10.2% on an operational basis and ahead of the roughly $16.77 billion consensus. Adjusted diluted EPS was $3.65, just short of the $3.71 expected — a miss the company attributed in part to a $0.17 unfavourable impact from acquired in-process research-and-development (IPR&D) expense. On a GAAP basis, diluted EPS was $2.03 and net earnings attributable to AbbVie were $3.61 billion. For the first half of 2026, revenues were $31.99 billion.

The company raised its full-year 2026 adjusted EPS guidance to $13.87–$14.07 and its revenue outlook to about $67.6 billion, an increase of roughly $300 million, while noting an anticipated $0.14 dilution from the pending Apogee acquisition. AbbVie is regarded as a 'Dividend King', having lifted its quarterly dividend to $1.64 per share from $1.55 in its most recent increase. These figures are drawn from AbbVie's Q2 2026 earnings release, its quarterly filing and the earnings call.

The Bull Case

The bull case is straightforward: the Humira succession is working. Skyrizi at a $5.5 billion quarterly run-rate is already a genuine mega-blockbuster, and both it and Rinvoq are still growing above 20%. Combined immunology sales of $8.8 billion, up nearly 15%, show the portfolio can grow through the patent cliff rather than merely tread water. Raised guidance, a diversified base beyond immunology in oncology, neuroscience and aesthetics, a robust dividend record, and the Apogee deal — which adds the IL-13 antibody zumilokibart for atopic dermatitis — all support the argument that AbbVie's growth is durable rather than a one-off rebound.

The Bear Case

The bear case centres on Quality of Earnings and balance-sheet strain. Adjusted EPS missed consensus, dragged by IPR&D and deal-related costs, and the wide GAAP-to-adjusted gap reflects heavy intangible amortisation. The $10.9 billion Apogee Acquisition adds near-term dilution (about $0.14 to 2026 EPS) and Leverage for Assets still in clinical development that carry trial risk. Humira continues to decline steeply, concentrating the group's fortunes on two drugs that will eventually face their own biosimilar and patent pressures. Rinvoq, as a JAK inhibitor, operates under a class-wide regulatory safety overhang, and the shares' muted reaction shows expectations are already elevated.

What Could Move the Stock Next?

The most important near-term catalyst is completion of the Apogee acquisition, expected in the third quarter of 2026, and any updated financial framing that follows. Investors will watch third-quarter results for continued Skyrizi and Rinvoq momentum and Humira's rate of decline, plus pipeline readouts across immunology, oncology and neuroscience. Regulatory decisions and label expansions for Rinvoq and Skyrizi, progress on Apogee's lead asset zumilokibart — in late-stage development for atopic dermatitis, with additional studies in asthma and eosinophilic oesophagitis — and further capital-return and dividend decisions are the other key swing factors.

Outlook

Can AbbVie finally leave the Humira hangover behind? On the evidence of the second quarter, it is very close. Skyrizi and Rinvoq together generate around $8 billion a quarter and are still growing above 20%, comfortably outpacing Humira's decline and driving group revenue and guidance higher. The complications are real — an earnings miss on IPR&D costs, added leverage and dilution from the Apogee deal, and eventual patent pressure on the successor drugs — but the strategic question posed by the headline increasingly answers itself. The hangover is fading; the harder task now is proving that the second act can compound for years, not merely replace what was lost.